We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GSK Ends Impax Partnership Due To Quality-Linked Rytary Delays
GSK Ends Impax Partnership Due To Quality-Linked Rytary Delays
May 3, 2013
After continuous stalling of Impax Pharmaceuticals’ Parkinson’s drug Rytary, GlaxoSmithKline (GSK) is pulling out of its development and marketing partnership with the smaller company.